MAPT and Alzheimer disease: According to Li et al. (2015), E-selectin levels in CSF are considerably higher in clinically diagnosed AD patients who did not have the usual AD CSF biomarker signature (i.e., low tau/Aβ42 ratio) compared to those who did have a positive biomarker signature.